Skip to main content
Terug
STVN logo

Stevanato Group S.p.A.

Datakwaliteit: 100%
STVN
NYSE Healthcare Medical - Instruments & Supplies
€ 14,18
▼ € 0,16 (-1,12%)
Marktkapitalisatie: 3,87B
Dagbereik
€ 14,18 € 14,92
52-Weeksbereik
€ 13,91 € 28,00
Volume
270.227
50D / 200D Gem.
€ 16,56 / € 22,06
Vorige Slotkoers
€ 14,34

Quick Summary

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (631 peers)

Metriek Aandeel Sector Mediaan
P/E 28,8 0,3
P/B 2,6 3,0
ROE % 9,3 3,7
Net Margin % 11,8 3,8
Rev Growth 5Y % 7,8 10,0
D/E 0,3 0,2

Koersdoel Analisten

Hold
€ 24,50 +72.8%
Low: € 17,50 High: € 32,00
Forward K/W
23,36
Forward WPA
€ 0,61
WPA Groei (sch.)
+0,0%
Omzet Sch.
1,27B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 1,24
€ 1,22 – € 1,25
 1,78B 1
FY2029 € 1,09
€ 1,08 – € 1,10
 1,64B 1
FY2028 € 0,90
€ 0,89 – € 0,91
 1,53B 1

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-03-04 € 0,20 € 0,21 +6,5%
2025-11-06 € 0,14 € 0,16 +14,3%
2025-08-05 € 0,11 € 0,12 +9,1%
2025-05-08 € 0,10 € 0,11 +10,0%
2025-03-06 € 0,20 € 0,20 0,0%
2024-11-05 € 0,14 € 0,13 -7,7%
2024-08-06 € 0,11 € 0,10 -10,0%
2024-05-09 € 0,12 € 0,09 -27,3%

Dividend History

4 yr streak

Yield

0,00%

Payout Ratio

0,11%

Growth (3Y)

6,09%

Growth (5Y)

N/A

Ex-Date Payment Date Amount Yield
Jun 05, 2025 Jul 17, 2025 € 0,06 0,26%
Jun 04, 2024 Jul 15, 2024 € 0,06 0,31%
Jun 07, 2023 Jul 17, 2023 € 0,06 0,21%
Jun 13, 2022 Jul 13, 2022 € 0,05 0,34%

Belangrijkste Punten

Revenue grew 7,80% annually over 5 years — modest growth
Debt/Equity of 0,32 — conservative balance sheet
Generating 21,44M in free cash flow
Revenue growth is decelerating — 1Y growth trails 5Y average by 4,59%

Groei

Revenue Growth (5Y)
7,80%
Revenue (1Y)3,21%
Earnings (1Y)14,01%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
9,29%
ROIC7,02%
Net Margin11,78%
Op. Margin16,07%

Veiligheid

Debt / Equity
0,32
Current Ratio1,74
Interest Coverage8,40

Waardering

P/E Ratio
28,83
Forward P/E23,36
P/B Ratio2,61
EV/EBITDA23,00
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 3,21% Revenue Growth (3Y) 2,46%
Earnings Growth (1Y) 14,01% Earnings Growth (3Y) -3,98%
Revenue Growth (5Y) 7,80% Earnings Growth (5Y) -0,01%
Profitability
Revenue (TTM) 1,14B Net Income (TTM) 134,28M
ROE 9,29% ROA 5,28%
Gross Margin 28,99% Operating Margin 16,07%
Net Margin 11,78% Free Cash Flow (TTM) 21,44M
ROIC 7,02% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,32 Current Ratio 1,74
Interest Coverage 8,40
Dividends
Dividend Yield 0,00% Payout Ratio 0,11%
Dividend Growth (3Y) 6,09% Dividend Growth (5Y) N/A
Consecutive Div Years 4 yrs
Valuation
P/E Ratio 28,83 Forward P/E 23,36
P/B Ratio 2,61 P/S Ratio 3,40
PEG Ratio 2,50 Forward PEG N/A
EV/EBITDA 23,00 Fwd EV/EBITDA 13,34
Forward P/S 3,04 Fwd Earnings Yield 4,28%
FCF Yield 0,55%
Market Cap 3,87B Enterprise Value 4,21B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,14B 1,10B 1,09B 983,68M 843,92M
Net Income 134,28M 117,78M 145,63M 142,85M 134,32M
EPS (Diluted) 0,49 0,43 0,55 0,53 0,53
Gross Profit 330,33M 302,32M 339,89M 319,80M 265,41M
Operating Income 183,08M 161,14M 200,72M 192,43M 162,23M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2,54B 2,33B 2,07B 1,66B 1,42B
Total Liabilities 1,06B 924,43M 938,93M 663,79M 577,18M
Shareholders' Equity 1,49B 1,40B 1,13B 996,13M 842,07M
Total Debt 470,70M 428,97M 396,59M 218,37M 244,29M
Cash & Equivalents 130,54M 98,27M 69,60M 228,74M 411,04M
Current Assets 934,40M 880,12M 861,89M 845,78M 865,97M
Current Liabilities 535,57M 477,47M 574,39M 462,50M 338,62M